Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

We aimed to characterize the pharmacokinetics and pharmacodynamics of drotrecogin alfa (activated) (recombinant human activated protein C) in patients with severe sepsis.

[1]  G. Bernard,et al.  Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis , 2001, Critical care medicine.

[2]  C. Esmon,et al.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis. , 2001, The New England journal of medicine.

[3]  B. Grinnell,et al.  Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis , 2001, Critical care medicine.

[4]  J. Dhainaut,et al.  Activated protein C versus protein C in severe sepsis , 2001, Critical care medicine.

[5]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[6]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[7]  M. Vervloet,et al.  Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic Shock , 1998, Seminars in thrombosis and hemostasis.

[8]  F. España,et al.  Quantification of Circulating Activated Protein C in Human Plasma by Immunoassays - Enzyme Levels are Proportional to Total Protein C Levels , 1996, Thrombosis and Haemostasis.

[9]  C. Esmon.  Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  C. Esmon.  Molecular Events that Control the Protein C Anticoagulant Pathway , 1993, Thrombosis and Haemostasis.

[11]  M. Scully,et al.  Activation of Protein C and Its Distribution between Its Inhibitors, Protein C Inhibitor, α1-Antitrypsin and α2-Macroglobulin, in Patients with Disseminated intravascular Coagulation , 1993, Thrombosis and Haemostasis.

[12]  R. Marlar,et al.  Contribution of Plasma Proteinase Inhibitors to the Regulation of Activated Protein C in Plasma , 1993, Thrombosis and Haemostasis.

[13]  J. Griffin,et al.  Direct detection of activated protein C in blood from human subjects. , 1992, Blood.

[14]  J. Griffin,et al.  Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. , 1990, Circulation.

[15]  K. Takatsuki,et al.  Effect of Protein C and Activated Protein C on Coagulation and Fibrinolysis in Normal Human Subjects , 1990, Thrombosis and Haemostasis.

[16]  J. Griffin,et al.  Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. , 1989, Blood.

[17]  J. Griffin,et al.  Inhibition and complexation of activated protein C by two major inhibitors in plasma. , 1989, Blood.

[18]  P. Vokonas,et al.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. , 1987, The Journal of clinical investigation.